lundi 22 mai 2017

Onco Actu du 22 mai 2017

3.1 Tabac

Smokers will spend around £2000 a year on cigarettes as plain, standardised packs come into full force [Cancer Research UK]

This is the end of tobacco advertising [Cancer Research UK]

Cigarettes sold in plain green packs under new rules [BBC News]

3.3 Prévention - Vaccins

Vaccine may reduce HPV infections that cause some oral cancers [Cancer Research UK]

4. Dépistage, diagnostic et pronostic

New imaging technique aims to ensure surgeons completely remove cancer [WUSTL]

5.12.2 Immunothérapies - CAR-T

A father’s plea: The FDA needs to make sure that Juno’s lethal disaster isn’t repeated

5.12.6 Immunothérapies - AMM

Merck’s checkpoint star Keytruda grabs another FDA OK, steering past wreckage of a Roche disaster [EndPoints]

5.2 Pharma

XBiotech's worst fears come true as EMA rejects colorectal cancer drug [FierceBiotech]

European Medicines Agency Validates Application for Bristol-Myers Squibb’s Sprycel (dasatinib) in Children with Chronic Myelogenous Leukemia [BMS]

The EMA rejects XBiotech’s cancer drug after an embarrassing PhIII — but they’re not giving up [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

FDA Oncology Center of Excellence Moves Forward on Coordinated Clinical Reviews, Integrated Approach to the Clinical Evaluation of Oncology Products [AJMC]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 May 2017 [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC) [Novartis]

CHMP backs Novartis's Zykadia for first-line use in lung cancer [Reuters]

5.5.8 ASCO (poumon)

Targeted drug delays relapse of intermediate-stage lung cancer [Cancer Research UK]

6.1 Observation

One in Five Cancers Diagnosed in the United States Is a Rare Cancer [ACS]

6.6 Publications

Forty-first Take: Boycott BioRχiv! [The Genome's Take]

Retractions in cancer research: a systematic survey [Research Integrity and Peer Review]